Clinical Evidence Integrity: The $12 Billion Regulatory Delay Crisis Reshaping Pharma and Healthcare
The $80 billion clinical trials market faces a data integrity crisis: 34% of FDA deficiency findings involve audit trail and timestamp failures, while 41% of contested malpractice claims dispute EHR temporal integrity. With data integrity delays costing pharma $12 billion annually and telemedicine consent disputes rising 38%, we project the healthcare evidence infrastructure market at $6.8 billion by 2030 — driven by converging mandates from the FDA, EMA, and MHLW.
Vlaander LTD
Read →